119 related articles for article (PubMed ID: 22554863)
21. [Biopharmaceutics classification and absorption mechanisms primary study on four kinds of flavonoids].
Li HF; Zhang D; Qu WJ; Wang HL; Liu Y; Borjigdai A; Cui J; Dong ZQ
Zhongguo Zhong Yao Za Zhi; 2016 Apr; 41(7):1198-1203. PubMed ID: 28879731
[TBL] [Abstract][Full Text] [Related]
22. Integrating theoretical and experimental permeability estimations for provisional biopharmaceutical classification: Application to the WHO essential medicines.
Cabrera-Pérez MÁ; Pham-The H; Cervera MF; Hernández-Armengol R; Miranda-Pérez de Alejo C; Brito-Ferrer Y
Biopharm Drug Dispos; 2018 Jul; 39(7):354-368. PubMed ID: 30021059
[TBL] [Abstract][Full Text] [Related]
23. The complexity of intestinal permeability: Assigning the correct BCS classification through careful data interpretation.
Zur M; Hanson AS; Dahan A
Eur J Pharm Sci; 2014 Sep; 61():11-7. PubMed ID: 24262076
[TBL] [Abstract][Full Text] [Related]
24. Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system.
Lentz KA; Hayashi J; Lucisano LJ; Polli JE
Int J Pharm; 2000 Apr; 200(1):41-51. PubMed ID: 10845684
[TBL] [Abstract][Full Text] [Related]
25. Transintestinal transport mechanisms of 5-aminosalicylic acid (in situ rat intestine perfusion, Caco-2 cells) and Biopharmaceutics Classification System.
Smetanová L; Stětinová V; Kholová D; Kuneš M; Nobilis M; Svoboda Z; Květina J
Gen Physiol Biophys; 2013 Sep; 32(3):361-9. PubMed ID: 23846255
[TBL] [Abstract][Full Text] [Related]
26. Transepithelial transport of ambroxol hydrochloride across human intestinal Caco-2 cell monolayers.
Stetinová V; Smetanová L; Kholová D; Svoboda Z; Kvetina J
Gen Physiol Biophys; 2009 Sep; 28(3):309-15. PubMed ID: 20037197
[TBL] [Abstract][Full Text] [Related]
27. The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver?
Blume HH; Schug BS
Eur J Pharm Sci; 1999 Dec; 9(2):117-21. PubMed ID: 10620723
[TBL] [Abstract][Full Text] [Related]
28. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests.
Kim JS; Mitchell S; Kijek P; Tsume Y; Hilfinger J; Amidon GL
Mol Pharm; 2006; 3(6):686-94. PubMed ID: 17140256
[TBL] [Abstract][Full Text] [Related]
29. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.
Lindenberg M; Kopp S; Dressman JB
Eur J Pharm Biopharm; 2004 Sep; 58(2):265-78. PubMed ID: 15296954
[TBL] [Abstract][Full Text] [Related]
30. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
Davit BM; Kanfer I; Tsang YC; Cardot JM
AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
[TBL] [Abstract][Full Text] [Related]
31. Donepezil Hydrochloride BCS Class Ambiguity: Relevant Aspects to be Considered in Drug Classification.
de Campos DP; Silva-Barcellos NM; Caldeira TG; Mussel WDN; Silveira V; de Souza J
J Pharm Sci; 2022 Nov; 111(11):3064-3074. PubMed ID: 35787368
[TBL] [Abstract][Full Text] [Related]
32. Qualification of In Vitro Dissolution Absorption System 2 (IDAS2) with Caco-2 and MDCK Cell Monolayers: Dose Sensitivity Study Using BCS Class I and III Drugs.
Higashino H; Develin CF; Higashino C; Lim TC; Miezeiewski BJ; Rawa SL; Strab RJ; Patel R; Bhoopathy S
Biol Pharm Bull; 2024; 47(6):1123-1127. PubMed ID: 38839364
[TBL] [Abstract][Full Text] [Related]
33. Leveraging BCS in Development: A Case Study.
Hoaglund Hyzer CS; Fadda HM; Rodriguez JO; Aburub A
Mol Pharm; 2015 Oct; 12(10):3685-90. PubMed ID: 26365521
[TBL] [Abstract][Full Text] [Related]
34. The biopharmaceutics of successful controlled release drug product: Segmental-dependent permeability of glipizide vs. metoprolol throughout the intestinal tract.
Zur M; Cohen N; Agbaria R; Dahan A
Int J Pharm; 2015 Jul; 489(1-2):304-10. PubMed ID: 25957705
[TBL] [Abstract][Full Text] [Related]
35. Comparing multilabel classification methods for provisional biopharmaceutics class prediction.
Newby D; Freitas AA; Ghafourian T
Mol Pharm; 2015 Jan; 12(1):87-102. PubMed ID: 25397721
[TBL] [Abstract][Full Text] [Related]
36. Current and evolving approaches for improving the oral permeability of BCS Class III or analogous molecules.
Dave VS; Gupta D; Yu M; Nguyen P; Varghese Gupta S
Drug Dev Ind Pharm; 2017 Feb; 43(2):177-189. PubMed ID: 27998192
[TBL] [Abstract][Full Text] [Related]
37. A Sensitive Medium-Throughput Method to Predict Intestinal Absorption in Humans Using Rat Intestinal Tissue Segments.
Da Silva LC; Da Silva TL; Antunes AH; Rezende KR
J Pharm Sci; 2015 Sep; 104(9):2807-12. PubMed ID: 25690454
[TBL] [Abstract][Full Text] [Related]
38. Optimizing solubility and permeability of a biopharmaceutics classification system (BCS) class 4 antibiotic drug using lipophilic fragments disturbing the crystal lattice.
Tehler U; Fagerberg JH; Svensson R; Larhed M; Artursson P; Bergström CA
J Med Chem; 2013 Mar; 56(6):2690-4. PubMed ID: 23432334
[TBL] [Abstract][Full Text] [Related]
39. The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol.
Zur M; Gasparini M; Wolk O; Amidon GL; Dahan A
Mol Pharm; 2014 May; 11(5):1707-14. PubMed ID: 24735251
[TBL] [Abstract][Full Text] [Related]
40. Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds.
Marino AM; Yarde M; Patel H; Chong S; Balimane PV
Int J Pharm; 2005 Jun; 297(1-2):235-41. PubMed ID: 15907606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
